Leadership

  • David C. Heimbrook, Ph.D.

    David C. Heimbrook, Ph.D.

    Laboratory Director, Frederick National Laboratory for Cancer Research

    David C. Heimbrook, Ph.D. David C. Heimbrook, Ph.D. Laboratory Director, Frederick National Laboratory for Cancer Research President, Leidos Biomedical Research, Inc.

    As President of Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Heimbrook is responsible for the comprehensive management and oversight of all scientific and operational activities conducted at Frederick National Laboratory for Cancer Research, a technology-driven Federally Funded Research and Development Center (FFRDC) supporting the NCI’s mission in Frederick, MD. He leads a staff of approximately 1,900 scientific, technical, and support professionals who perform basic and applied research in cancer, AIDS, and infectious disease and maintain a full suite of advanced technologies in areas such as nanotechnology, genomics and biomedical imaging.

    Heimbrook brings more than 20 years of experience in cancer research, translational medicine and organizational management to this position. He earned a bachelor’s degree in chemistry from Duke University and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University. Prior to joining Leidos, he was the global head of Discovery Oncology for the Pharma Research and Early Development (pRED) organization at Roche, where he worked for 8 years. Based in Nutley, New Jersey, but also leading oncology research efforts in Germany and Switzerland, Heimbrook was responsible for developing and implementing Roche’s oncology research strategy, including personalized healthcare and partnering relationships, and transitioning compounds from discovery through clinical proof-of-concept. Heimbrook helped transition over a dozen molecules into clinical development and led internal discovery efforts at Roche supporting the development of vemurafenib, which was the first RAF inhibitor approved for the treatment of patients with metastatic melanoma harboring specific V600 mutations in this protein. Prior to joining Roche, Heimbrook was the head of Cancer Research at Merck, based in West Point, PA, where he worked for 16 years. He has co-authored 6 patents and over 70 scientific publications.

  • Kathy Terlesky, Ph.D.

    Kathy Terlesky, Ph.D.

    Chief Operating Officer

    Kathy Terlesky, Ph.D. Kathy Terlesky, Ph.D. Chief Operating Officer

    Terlesky received both her Bachelor’s degree and her Doctorate from Virginia Tech. She then worked as a research scientist with Monsanto and General Dynamics before moving to a project manager role. She joined our corporate parent, Leidos Holdings (formerly SAIC) in 2006 as the Deputy Chief Technology Officer in the Intelligence Systems Business Unit, and then assumed the role of Vice President and Division Manager within the National Security sector. In this role, she implemented new quality management and business models which significantly improved productivity and profitability, while garnering multiple technology innovation awards.

  • Barry L. Gause, M.D.

    Barry L. Gause, M.D.

    Chief Medical Officer

    Barry L. Gause, M.D. Barry L. Gause, M.D. Chief Medical Officer Director, Clinical Research Directorate Clinical Group

    Gause received his Doctor of Medicine degree from Michigan State University’s College of Human Medicine in 1976. He trained in Internal Medicine and Pediatrics at Emory University in Atlanta, Georgia followed by a 4-year fellowship in Medical Oncology at the National Cancer Institute. After completing his postdoctoral training, Gause was a faculty member at the Howard University Cancer Center where he attained the position of Chief of Medical Oncology before returning to the NCI. During his NCI tenure, he made contributions in therapeutic vaccines for lymphoma, melanoma, cervical, and ovarian cancer, in addition to being a senior staff member on the Lymphoma Service and the Director of the Medical Oncology Fellowship program. After a 22-year career with the NCI, Gause joined SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013) in November of 2006 as the inaugural Director of the Clinical Research Directorate (CRD). This program provides regulatory, clinical trials and project management support to clinical trial programs within NCI and NIAID, and affords quality assurance management to the Vaccine Pilot Plant and the Biopharmaceutical Development Programs of the Frederick National Lab. He has continued as a member of the Medical Oncology Branch providing clinical care for patients on the Lymphoma Service in the inpatient and outpatient setting.

    In September 2008, Gause was appointed as the Chief Medical Officer of SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013). This group consists of 4 directorates; Biopharmaceutical Development Program, Applied and Developmental Research, Vaccine Clinical Materials Program, and the CRD. This provides synergy and collaboration between those Frederick National Lab directorates at the clinical end of the translational research spectrum.

  • Beth Baseler

    Beth Baseler

    Director, Clinical Monitoring Research Program

    Beth Baseler Beth Baseler Director, Clinical Monitoring Research Program

    Baseler brings more than 35 years in the clinical research and clinical laboratory operations management environment. She holds a bachelor’s degree in biology and a master’s in administration and management. Prior to assuming her current position as the Director of the Clinical Monitoring Research Program, she held various positions within the Operations and Technical Support Contract for the NCI-Frederick: Director of Administration for the Applied Developmental Research Program, Acting Technical Director of the Biopharmaceutical Development Program, Clinical Services Program Manager, Scientific Program Administrator, and technical laboratory research positions. Baseler has a long history of directing operational and management support to domestic and international clinical studies in all aspects of clinical studies development and management including; regulatory affairs, clinical site development, data monitoring, clinical monitoring, pharmacovigilance, quality assurance and control, protocol navigation, training, project/program management and logistical support. In the last 15+ years, she has directed an expanding operation providing quality programmatic and clinical operations research management support to a variety of high-profile National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID) initiatives. A major component of the program provides comprehensive regulatory and clinical trials management support to 400+ domestic and international clinical trials for NCI and NIAID intramural clinical researchers investigating cancer, HIV, and a variety of infectious diseases. More recently, Baseler is leading the rapid response to the Ebola Response Program in West Africa and the Vaccine Research Center’s Zika 705 study.

  • Michael Baseler, Ph.D.

    Michael Baseler, Ph.D.

    Director, Applied and Developmental Research Directorate

    Michael Baseler, Ph.D. Michael Baseler, Ph.D. Director, Applied and Developmental Research Directorate

    Baseler is a clinical lab director at the Frederick National Lab. He received his B.S. from Clarion State University in Pennsylvania before attending West Virginia University in Morgantown, West Virginia where he received his Masters and Ph.D. in Microbiology and Immunology. After finishing his degree, Baseler took a Post Doc position with the American Biological Company in Malvern, Pennsylvania.

    In 1986, Baseler was hired as head of the AIDS Support Laboratory for the Clinical Immunology Services, PRI, at NCI-FCRDC. In 1991, he was promoted to Head of the Clinical Immunology Services and 2 years later to Head of the Clinical Services Program under SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013). Baseler is now the Director of the Applied and Developmental Research Directorate which consists of 34 clinical and research laboratories at the Frederick National Lab, focusing on cancer and infectious diseases. These laboratories support DCTD, CCR, DCEG, DCP, NCI, and NIAID.

  • Frank Blanchard

    Frank Blanchard

    Director, Public Affairs and Communications

    Frank Blanchard Frank Blanchard Director, Public Affairs and Communications

    Blanchard oversees a diverse program of outreach to constituents at the local, state, and national levels; companywide internal communications; and creative, editorial, and production services that support Frederick National Lab and NCI at Frederick. Blanchard received a bachelor’s degree in journalism from the University of Florida. He began his career as a newspaper reporter and then wire service editor for the Associated Press bureau in Atlanta. He covered politics, civil rights, and the earliest federal health alerts pointing to the AIDS crisis. He left journalism in 1985 to be a science writer for the University of Michigan news office, covering everything from physics to public health to engineering. He subsequently worked for two major foundations supporting research and education in the biomedical sciences. He was senior information officer for the Howard Hughes Medical Institute in Bethesda, Md., and then director of communications for the Whitaker Foundation in Arlington, Va. When the Whitaker Foundation closed in 2006, Blanchard joined the staff of what was then SAIC-Frederick as director of public affairs. He currently serves on the board of the Fort Detrick Alliance, is a member of the Frederick County Community Cancer Coalition and Frederick County Health Coalition, participates in the Major Employers Group of the Frederick County Chamber of Commerce, and volunteers with the American Cancer Society’s Road to Recovery and Germantown HELP. 

  • Tim Boyle

    Tim Boyle

    Director, Financial Operations Directorate

    Tim Boyle Tim Boyle Director, Financial Operations Directorate

    Boyle has been with SAIC/Leidos since 2009 and brings 30 years of experience in federal, commercial, and international financial management. In his tenure with the company, Boyle has held several VP of Finance roles, the most recent with Leidos’ Surveillance & Reconnaissance Group with annual revenues exceeding $1 Billion. In 2014, Boyle was a member of the team that successfully won the UK Ministry of Defence (MOD) contract to be the preferred bidder to manage its defense logistic commodities and services. Known as Logistic Commodities Services Transformation (LCST), the 13-year contract involves procuring non-military essentials such as food and medical supplies, and providing storage and distribution services for the UK's armed forces at home and abroad. Boyle successfully passed the American Institute of Certified Accounting Examination in November 1992.

  • Terri Bray

    Terri Bray

    Director, Environment, Healthy, and Safety Directorate

    Terri Bray Terri Bray Director, Environment, Healthy, and Safety Directorate

    As director of Environment, Health and Safety, Bray brings more than more twenty years of experience in program development and implementation, organizational change management, and facilities and research program management. She has led many high-impact project teams to deliver multiple critical and first-of-its-kind projects related to facilities, organizational changes, and management systems. Prior to joining Leidos Biomedical Research, Inc. in December 2013, Bray was the Deputy Director of Environment, Safety and Quality Assurance at Argonne National Laboratory and held a number of progressively responsible nuclear materials research and facilities management positions there. She received a B.S. in Nuclear Engineering from Kansas State University, a M.S. in Nuclear Engineering and Engineering Physics from the University of Wisconsin-Madison, and an M.B.A. in Operations Management from DePaul University.

  • Mary Carrington, Ph.D.

    Mary Carrington, Ph.D.

    Director, Basic Science Program

    Mary Carrington, Ph.D. Mary Carrington, Ph.D. Director, Basic Science Program

    Mary Carrington is the Director of the Basic Science Program at the Frederick National Lab, where she is responsible for the guidance and oversight of a large, diverse group of scientists performing investigator-initiated, hypothesis-driven basic research in cancer and AIDS. She is also a Senior Principal Scientist at the National Cancer Institute and heads the HLA Immunogenetics Laboratory in the Cancer and Inflammation Program. Her primary research interests focus on the role of host genetics in cancer, autoimmunity and infectious disease pathogenesis.

    Carrington graduated from The University of Kansas with a B.S. in Education, later obtaining her M.S. and Ph.D. in Immunobiology from Iowa State University. She performed her postdoctoral studies in the departments of Immunology and Microbiology at Duke University and the University of North Carolina, after which she joined the Immunology Department at Duke University as a faculty member. She moved to the National Cancer Institute at Frederick in 1989.

  • Bernard Courtney, Ph.D.

    Bernard Courtney, Ph.D.

    Director, Project Management Operations Office

    Bernard Courtney, Ph.D. Bernard Courtney, Ph.D. Director, Project Management Operations Office

    Courtney joined Leidos Biomedical Research, Inc. with decades of federal experience in Army medical research, Homeland Security forensics, threat characterization, and development of technical analytic systems for the intelligence community. In the private sector, he has experience with advising National Security leaders, developing business, and directing a not-for-profit sample analysis laboratory. He has spent many years in Frederick, most recently as the federal director of the National Biodefense Analysis and Countermeasures Center for DHS. Here he oversaw the transition of the operations to a FFRDC.

    Courtney spent 10+ years in uniform with the Navy and the Army. He received his B.S. in Agronomy from Auburn University and his Ph.D. in Biochemistry and Molecular Biology from the University of Florida.

  • Beverly Hayes

    Director, Contracts and Acquisitions

    Beverly Hayes Director, Contracts and Acquisitions

    Hayes joined the Frederick National Lab with significant expertise and experience with clients in federal, state, and local, international and commercial markets. Over the last 20+ years, she has led the negotiations and administration of large-dollar-value long-term contracts and subcontracts. Those contracts required her to leverage her teams in support of the program managers and internal organizations such as project control, finance, human resources, communications and accounting. Hayes's career included several years with SAIC as the Deputy Director of Corporate Contracts. In that role she worked closely with members of the current Leidos Corporate management team. Her professional background includes leading cross-functional teams responsible for contracts and subcontracts administration, new business and task-order pricing, property management, supplier diversity and purchasing. She views her biggest achievements in terms of her ability to ensure collaboration and cohesiveness among the teams she leads, and with their internal and external clients. Hayes is focused on understanding the business requirements and having her team contribute to success, while also enjoying their jobs and being proud of their contributions. She received both her BBA and MBA from Averett University and encourages everyone to take the time to gain additional knowledge and apply it wherever they can.

  • Claudia Haywood

    Claudia Haywood, Esq.

    Director, Intellectual Property and Strategic Agreements

    Claudia Haywood, Esq. Claudia Haywood Director, Intellectual Property and Strategic Agreements

    Haywood serves as the Director of Intellectual Property and Strategic Agreements. In this role, she is responsible for managing the intellectual property portfolio at Leidos Biomed and providing management oversight for intellectual property, research administration, and research compliance issues that occur as a part of operations and the ongoing research. In addition, Haywood is responsible for drafting, reviewing, and negotiating strategic agreements, e.g. confidentiality agreements, material transfers, licenses, collaborative agreements, etc. In this role, she works closely with the research staff and the Partnership Development Office to ensure compliance with the contractual requirements and the adequacy of the legal terms and conditions. 

    Haywood brings more than 20 years of experience in research administration, technology transfer, and legal services to this position. She has worked in various areas including research integrity and misconduct, research compliance, including human subjects compliance, animal care and use, and institutional biosafety, contract compliance, and HIPAA Privacy and Security. She earned a bachelor’s degree and a Master's of Business Administration from Virginia Commonwealth University. She also earned a Juris Doctor from the University of Maryland School of Law and a Doctor of Public Administration from the University of Baltimore. Prior to joining Leidos Biomedical Research, she served as Assistant General Counsel at the J. Craig Venter Institute for six years and Regional Research Administrator and In-house Counsel at the Providence Health System-Oregon in Portland, Oregon for six years. Prior to that, Haywood served as Assistant Vice President at the University of Maryland Biotechnology Institute in Baltimore, Maryland. 

  • Shannon Jackson

    Shannon Jackson

    Director, Contracts

    Shannon Jackson Shannon Jackson Director, Contracts

    As Director of Contracts, Jackson brings more than 20 years of experience leading and performing in contracts, procurement, and logistics at commercial entities and governmental agencies. He has led contracts and procurement teams within both the manufacturing and services sectors with some of the leading organizations in their respective industries. He is a member of the National Contract Management Association (NCMA) and is a former chapter vice-president. Jackson holds a bachelor’s degree in business administration and earned his MBA from Texas A&M-Commerce. He completed advanced professional and executive education at Villanova University and Cornell University. Prior to embarking on a career as contracts and procurement professional, Jackson served for 5 years in the U.S. Marine Corps.

  • Stephen Jones, Ph.D.

    Stephen Jones, Ph.D.

    Director, Laboratory Animal Sciences Program

    Stephen Jones, Ph.D. Stephen Jones, Ph.D. Director, Laboratory Animal Sciences Program

    Jones joined Leidos Biomedical Research, Inc. in April 2016 as Director of the Laboratory Animal Sciences Program for the NCI in Frederick and Bethesda. He comes to Frederick National Lab with more than 20 years of experience as a researcher in the NIH extramural program. As a Professor at the University of Massachusetts Medical School (UMMS), Jones taught genetics, cell signaling, and cancer biology to graduate and medical students, maintained an active research program, consulted for biotech companies and industry, and served on editorial boards, study sections, and numerous other national committees.

    Prior to joining the faculty at UMMS, Jones completed his undergraduate studies in biology at the University of Virginia, his doctoral studies in microbiology at Vanderbilt University School of Medicine, and his post-doctoral studies in metabolic disorders and in cancer biology at Baylor College of Medicine. His research program at UMMS explored the function and regulation of tumor suppressor genes in development and cancer, and he was the Founder and Director of the UMMS Transgenic Animal Modeling Core and the UMMS Gene Targeting and Stem Cell Core. Jones has more than 115 publications in scientific journals, and a broad background and keen interest in using genetically engineered rodents to model human disease and perform preclinical and translational cancer research.

  • Jeffrey D. Lifson, M.D.

    Jeffrey D. Lifson, M.D.

    Director, AIDS and Cancer Virus Program

    Jeffrey D. Lifson, M.D. Jeffrey D. Lifson, M.D. Director, AIDS and Cancer Virus Program

    Lifson received his M.D. from Northwestern University Medical School in 1982, followed by residency and research fellowship training in the Department of Pathology at the Stanford University School of Medicine. He became involved in AIDS-related research in 1983, playing a key role in establishing the first program in the United States to try to prevent transfusion-mediated transmission of AIDS through laboratory testing, while also conducting basic in vitro studies of AIDS pathogenesis. After several years of continuing research in AIDS pathogenesis while working in the biotechnology industry, Lifson moved to SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013) in 1995, establishing the Retroviral Pathogenesis Section within the AIDS Vaccine Program. His work there has focused on the continuing development and application of quantitative virological and immunological methods for understanding retroviral pathogenesis and evaluating approaches for the prevention and treatment of retroviral infection and AIDS. In 2002, Lifson was named the director of the AIDS Vaccine Program, which became the AIDS and Cancer Virus Program in 2008.

  • David Lindsay, Ph.D.

    David Lindsay, Ph.D.

    Director, Vaccine Clinical Materials Program

    David Lindsay, Ph.D. David Lindsay, Ph.D. Director, Vaccine Clinical Materials Program

    David Lindsay, Ph.D. has been the Directorate head of the Vaccine Clinical Materials Program since March 2015. During his first 17 months of tenure at the Frederick pilot plant, he led the ramp-up of VRC01 monoclonal antibody (mAb) production to meet demands for an ongoing anti-HIV antibody-mediated prevention (AMP) clinical trial, and he spearheaded a capacity expansion initiative to enable sustained dual-product GMP manufacturing activities. Currently, Lindsay and his team are actively engaged in the production of ZIKA plasmid DNA vaccine candidates for high visibility Phase I and II clinical trials led by NIH/ NIAID’s Vaccine Research Center (VRC).

    Prior to joining Leidos Biomedical Research, Lindsay gained R&D and manufacturing experience over 12 years at MedImmune LLC in both Gaithersburg, MD and Frederick, MD locations. His range of experience included process development and clinical manufacturing support for various mAb-based products, GMP manufacturing of commercial Synagis (palivizumab) at 2000-Liter scale, and tech transfer, manufacture to facility licensure for partner Merck’s Keytruda mAb at 12,000-Liter bioreactor scale. Prior to MedImmune, Lindsay spent 7 years at Schering-Plough Research Institute in Union, NJ in Biotech Development division. He obtained his Ph.D. in Bio/Chemical Engineering from The Johns Hopkins University in Baltimore, MD.

  • Chris March

    Chris March

    Director, Human Resources

    Chris March Chris March Director, Human Resources

    As Director of Human Resources, March brings twenty years of experience in employee relations, recruitment and retention, Affirmative Action, compensation, benefits, training, employee development and organization effectiveness. Prior to joining Leidos Biomedical Research, Inc., March was the Head of Human Resources for Lonza Walkersville, Inc. and has held a number of progressively responsible human resources positions at Knorr Brake Company, LLC; MedImmune, LLC; Randstad; BP, LLC; and Corning, Inc. March received a B.S in Business Administration from Nazareth College in Rochester, NY.

  • Gautam (George) Mitra, Ph.D.

    Gautam (George) Mitra, Ph.D.

    Director, Biopharmaceutical Development Program

    Gautam (George) Mitra, Ph.D. Gautam (George) Mitra, Ph.D. Director, Biopharmaceutical Development Program

    Mitra joined SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013) as Director of the Biopharmaceutical Development Program (BDP), in May 1999 in support of the Biological Resource Branch of the Developmental Therapeutic Program of the National Cancer Institute. As the director of the program, he manages all biological product development and clinical production of natural products, recombinant proteins, monoclonal antibodies, recombinant immunotoxins, plasmid DNA, viral vaccines and other related entities.

    Mitra’s 24 years of previous biotech industry experience includes executive management positions at Smith Kline Beecham’s Vaccine R&D facility at Rixensart, Belgium and Bayer USA’s biological R&D-manufacturing division at Berkeley, California. He has contributed towards development and licensing of numerous biological products (>10 licensed biologicals) and is listed as a discoverer on 20 issued patents. His Ph.D. is in Bio-Chemical Engineering from the University of California at Berkeley, California.

  • Dwight Nissley, Ph.D.

    Dwight Nissley, Ph.D.

    Director, Cancer Research Technology Program

    Dwight Nissley, Ph.D. Dwight Nissley, Ph.D. Director, Cancer Research Technology Program

    Nissley joined the SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013) Basic Research Program (BRP) in 2001. His research efforts focused on mobile elements, retrotransposition, mechanisms of reverse transcription, the fidelity of HIV-1 reverse transcriptase, and the evolution of drug resistance during HIV-1 infection. In 2004, he became the Scientific Program Manager for the BRP where he used his background in experimental, hypothesis-driven biological research to oversee and manage basic research efforts carried out in support of the NCI Center for Cancer Research. In 2008, he initiated the reorganization of the BRP into the current Basic Science Program (BSP) and became Associate Director for the BSP where he directed and managed the day-to-day operational and scientific efforts of a broad-ranging research program. In 2012, Nissley was named the Director of the Advanced Technology Program (renamed Cancer Research Technology Program Directorate in 2013).

  • Jim Pannucci, Ph.D.

    Jim Pannucci, Ph.D.

    Director, Partnership Development Office

    Jim Pannucci, Ph.D. Jim Pannucci, Ph.D. Director, Partnership Development Office

    Jim Pannucci is the Director of the FNLCR Partnership Development Office. He is responsible for developing external collaborations that enhance the FNLCR and NCI. Pannucci is an experienced global health, biodefense, and emerging infectious disease scientist and organizational leader. He has 24 years of scientific and management experience that includes RNA structural biology, drug discovery, biodefense, and vaccine development. He relates his diverse experience and management skills to the business of science. He excels at boiling down complex concepts into simple solutions and engages his staff with brainstorming sessions and organizational vision setting. Pannucci’s scientific career began with characterizing antiviral therapeutics at the Schering-Plough Research Institute (now Merck & Co.), and then a Ph.D. (Microbiology) from the North Carolina State University. He was a postdoc at the Los Alamos National Laboratory, became a technical staff member, and eventually a Team Leader in the BioScience Division. Pannucci joined SAIC/Leidos in 2006 to support contracts with DHS (NBACC) and NIAID (Malaria vaccines), and led the Leidos Life Sciences division from 2011-2016. Prior to joining the Frederick National Lab, he was the Senior Director - Infectious Diseases at Southern Research, a CRO with drug development focus on global health and emerging infectious diseases. 

  • Rich Pendleton

    Rich Pendleton

    Director, Business Operations

    Rich Pendleton Rich Pendleton Director, Business Operations

    As Director of Business Operations, Pendleton provides support to the Directorates at the Frederick National Lab in the areas of operational and organizational management. He holds a bachelor’s degree in biology with a minor in chemistry, and an MBA and certification in contract management. Pendelton has held various positons in both the scientific and administrative programs at NCI-Frederick. He has more than 30 years of experience working in scientific and management positions.

    Pendleton previously worked at Martin Marietta where he oversaw environmental impact studies on the Chesapeake Bay. At NCI-Frederick, he worked in the Environmental Research Section and then held scientific program management positions before joining the Financial and Administrative Systems. Pendleton assumed responsibility for oversight of financial and administrative systems in support of NCI-Frederick Programs and established the Contract Management Office to provide a single point of contact for contract management and operational issues with the goal to increasing response time and eliminating duplication.

    He received the SAIC-Frederick, Inc. Distinguished Career Service Award in 2001 for innovation in managing the OTS financial and contract administrative departments. Pendleton is a member of the National Contract Management Association (NCMA) and past president of the Frederick Chapter of the NCMA. He is also a member of the Project Management Institute. He served as the Chairperson of the Frederick County Board of Education Ethics Committee and is a graduate of the 2011 Leadership Frederick County Program. Pendleton is currently the Director for the Leadership Frederick County Executive Council.

  • Andrew Quong, Ph.D.

    Andrew Quong, Ph.D.

    Director, Strategic Scientific Initiatives & Partnerships Office

    Andrew Quong, Ph.D. Andrew Quong, Ph.D. Director, Strategic Scientific Initiatives & Partnerships Office

    Andrew Quong joined the Frederick National Lab after serving as a faculty member in the Departments of Cancer Biology at Thomas Jefferson University and Oncology at Georgetown University. His research focused on systems biology approaches to understand mechanisms of breast cancer resistance and biomarkers of therapeutic response. He has published extensively and served on the editorial boards of Cancer Research and the American Journal of Pathology. Prior to his time in academia, Quong was a staff scientist and group leader at Lawrence Livermore National Laboratory and a Sr. Member of Technical Staff at Sandia National Laboratories. Andrew completed his postdoctoral research at the Naval Research Laboratory as a National Research Council Fellow. He received his doctorate in Physics from the University of California, Irvine and undergraduate degrees in Physics and Applied Mathematics from the University of California, Berkeley.

  • Brett Smith

    Brett Smith

    Director, Business Enterprise Systems

    Brett Smith Brett Smith Director, Business Enterprise Systems

    Smith brings over 25 years of experience building and implementing information technology products and systems in the government contracting and commercial sectors. Prior to joining Leidos Biomed, he was the Vice President of Engineering for a software and solutions company where he led product development, support and IT. During his term, he converted the development teams to Agile, modernized the corporate infrastructure, and led successful project executions for Federal, Civilian, and Intelligence agencies. Prior to that role, he managed an engineering consulting company in North Carolina, providing hardware and sofware design for the telecommunications and data communications industry. Smith received a B.S.E.E. from West Virginia University and an M.S. in Computer Engineering from North Carolina State University.

  • Dante Tedaldi, Ph.D., P.E.

    Dante Tedaldi, Ph.D., P.E.

    Director, Facilities Maintenance and Engineering

    Dante Tedaldi, Ph.D., P.E. Dante Tedaldi, Ph.D., P.E. Director, Facilities Maintenance and Engineering

    As Director of Facilities, Maintenance and Engineering Tedaldi provides leadership to a staff of 200 employees engaged in planning, design, and execution of facility improvements and advances for the technologically complex FNL facilities. The full-service operation, including in-house design-build, construction, maintenance and facilities management functions delivers highly customized creative solutions by integrating the scientific requirements of world-class cancer and AIDS researchers into planning and engineering disciplines as well as maintenance activities.

    Prior to joining Leidos Biomed, Tedaldi was employed for over 18 years by Bechtel Corporation and had demonstrated success in operations review, work process improvement, feasibility studies, and design and implementation of high-impact projects. He has led and influenced policy dialogue and conducted competitive assessments with far-reaching implications for conversion and reuse of former industrial facilities and military installations within the United States and Russia.

    He received both his B.E. in Chemical Engineering and M.E. in Environmental Engineering from Manhattan College and his Ph.D. in Civil Engineering from The University of Texas at Austin. He has a combined total of over twenty peer-reviewed technical publications, book chapters, and national and international conference presentations related to facilities management, environmental engineering and hazardous waste management. He is a licensed Professional Engineer in Maryland and Texas and a certified Six Sigma Black Belt.